TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03558607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months.
Study: NCT01502800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 761
Description: ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 761 Weekly Administration
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bi-Weekly Administration of ARQ 761
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study: NCT02773979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02014961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermal biopsy
Description: Skin biopsy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gastro-intestinal questionnaire
Description: Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gastro-intestinal questionnaire
Description: Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Whole-exome sequencing
Description: Whole-exome sequencing (WES)

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Whole-exome sequencing
Description: Whole-exome sequencing (WES)

Intervention type: GENETIC
Group type: OTHER
Intervention: Whole-exome sequencing
Description: Whole-exome sequencing (WES)
Study: NCT02813031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional meat products
Study: NCT01502800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two Consecutive Weeks Administration of ARQ 761 with one week of rest
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study: NCT02813031

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional meat products
Study: NCT04823338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conectar Jugando Online Program
Description: Online play sessions with modern board and card games guided by the study researchers
Study: NCT02879461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LUMBAR DESCOMPRESSION
Description: ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LUMBAR DESCOMPRESSION
Description: ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
Study: NCT04564352

Intervention type: DIETARY_SUPPLEMENT
Intervention: Adansonia digitata
Description: Juice of AD fruit
Study: NCT02476565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA-Supreme supraglottic device
Description: The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel supraglottic device
Description: The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
Study: NCT02505516

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Study: NCT00600964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX15-070MS
Description: A 60-minute or 3-hour IV infusion every 2-3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX15-070MS
Description: GX15-070MS at various doses and schedules
Study: NCT02256111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Study: NCT00659165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Detemir
Description: Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
Study: NCT00124150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate infusion
Description: 80mg per day
Study: NCT01764334

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional flow reserve
Description: Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional flow reserve
Description: Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed.
Study: NCT01163734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Intravenous treatment followed oral treatment for 13 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% and placebo tablet
Description: Intravenous treatment followed by oral treatment for 13 days
Study: NCT03748745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229
Description: tablet, oral, 600 mg once daily for day 1 to day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229
Description: tablet, oral, 600 mg once daily for day 8 to day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: tablet, oral, 60 mg once daily for day 8 to day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: tablet, oral, 60 mg once daily for day 1 to day 14
Study: NCT04777279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual physical exercise group
Description: The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individual Branched-Chain Amino Acids supplements group
Description: The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of physical exercise and nutrition supplements group
Description: The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
Study: NCT00734838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Microendoscope
Description: Using core biopsy and reduction mammoplasty tissue

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High Resolution Microendoscope
Description: Using core biopsy and reduction mammoplasty tissue
Study: NCT01513772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
Study: NCT00721994

Intervention type: DEVICE
Intervention: Cormet Hip Resurfacing System
Description: Cormet Hip Resurfacing System
Study: NCT03923127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elan and HealthDot
Description: Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
Study: NCT01421810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 1 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhCG
Description: 25 mcg IV
Study: NCT01771276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: g-Cath Suture Anchor Delivery Catheter
Description: Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
Study: NCT04007744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Given PO
Study: NCT04400214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Allergy Superheroes Training (FAST) Program
Description: The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Allergy Knowledge Intervention
Description: The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session.
Study: NCT04172974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth intervention
Description: Modules developed for depression and anxiety based on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT) and compassion-focused coping
Study: NCT02533843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
Study: NCT03395535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Selective Laser Trabeculoplasty Treatment Pathway
Description: Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primary Medical Treatment Pathway
Description: Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.
Study: NCT00690547

Intervention type: OTHER
Intervention: muscle activation
Description: activation of the muscle quadriceps femoris
Study: NCT01538875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
Study: NCT00847574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-fat
Description: 35% of calories from fat

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower-fat
Description: 20% of calories from fat
Study: NCT04334603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training Program
Description: The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training Program
Description: The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
Study: NCT02545712

Intervention type: OTHER
Intervention: Exposure to ethanol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to ethanol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to propylene glycol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to propylene glycol
Description: The drug source(s) and amount administered daily are noted.
Study: NCT04172974

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Treatment according to national clinical guideline (referral to GP)
Study: NCT02086071

Intervention type: PROCEDURE
Group type: OTHER
Intervention: re biopsy
Description: re biopsy depending on the location of the pathology
Study: NCT04324112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
Study: NCT04434235

Intervention type: OTHER
Intervention: axial load
Description: With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine

Intervention type: OTHER
Intervention: axial load
Description: With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
Study: NCT03022318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg tablets
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg tablets
Description: See arm/group descriptions